A Single-arm, Open-label, Multicenter Study of Enfortumab Vedotin (ASG-22CE) for Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer Who Previously Received Immune Checkpoint Inhibitor (CPI) Therapy

Trial Profile

A Single-arm, Open-label, Multicenter Study of Enfortumab Vedotin (ASG-22CE) for Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer Who Previously Received Immune Checkpoint Inhibitor (CPI) Therapy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Jul 2018

At a glance

  • Drugs Enfortumab vedotin (Primary)
  • Indications Bladder cancer; Urethral cancer; Urogenital cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Astellas Pharma; Seattle Genetics
  • Most Recent Events

    • 09 Jul 2018 According to a Seattle Genetics media release, enrolment has been completed in the cohort of patients with locally advanced or metastatic urothelial cancer who have been previously treated with both platinum chemotherapy and a checkpoint inhibitor (PD-L1 or PD-1), and company expects to report topline efficacy and safety results in the first half of 2019.
    • 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 03 Jun 2018 Design of this trial presented at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting, according to an Astellas Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top